We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Mcp7.0
Mucuna Pruriens Research
Likely helpsModerate safety
27 peer-reviewed studies
What the evidence says
Likely helps
Mucuna Pruriens appears to help in 3 of 3 studies with measurable effects — the evidence leans clearly favourable.
Most evidence is from high-quality meta-analyses and randomised trials published 2004–2026 with a typical study size of 60 participants.
Based on 27 studies · 1 meta-analysis · 10 RCTs · 560 total participants
Confidence
Moderate
What the studies found
3helped· 24 more without graded effect data
By outcome
Therapeutic & clinical
Likely helps18 studies
Parkinson's disease
Likely helps16 studies
Fertility & reproductiveMay support reproductive health and fertility markers · 4-12 weeks
Mostly mechanism / observational8 studies
Men's vitalitySupports testosterone and growth hormone via dopamine and L-DOPA · 4-8 weeks · Improved libido via dopamine and androgen pathways · 2-4 weeks
Mostly mechanism / observational5 studies
Safety profile
Mostly mechanism / observational4 studies
Neuroprotection & brain aging
Mostly mechanism / observational3 studies
Heart & blood pressure
Too few graded studies2 studies
By the numbers
Pulled from 23 studies with measurable effects
People studied
560
typical study: 60 people
Strongest designs
11
1 pooled, 10 randomised
Showed benefit
100%
3/3 studies
How long studies ran
1–3 months
1
3+ months
3
Populations Studied
Parkinson's disease patients10
Hypertensive patients1
Parkinson's disease patients in low-income countries1
Patients with neurodegenerative diseases1
Active research area
11 studies in the last 5 years · Latest meta-analysis: 2018
Although levodopa is indispensable for the symptomatic management of PD, emerging evidence supports the integration of plant-derived bioactive compounds as adjunct therapies with disease-modifying potential.
Aktaş E et al. · CNS neuroscience & therapeutics (2025)
Although levodopa is indispensable for the symptomatic management of PD, emerging evidence supports the integration of plant-derived bioactive compounds as adjunct therapies with disease-modifying potential.
Future research should prioritize improving bioavailability, developing standardized formulations, and conducting long-term clinical trials to evaluate the translational applicability of these natural agents in Parkinson's disease therapy.
2Neuroprotective potential of phytochemicals in Parkinson's disease managementSystematic ReviewCited 4×2025
Das S et al. · Cell biochemistry and biophysics (2025)
This review provides a comprehensive overview of the neuroprotective potential of phytochemicals in PD management, examining the mechanisms underlying PD pathogenesis and emphasizing neuroprotection.
It explores the historical and current research on medicinal plants like Mucuna pruriens, Curcuma longa, and Ginkgo biloba, and discusses the challenges in clinical translation, including ethical and practical considerations and the integration with conventional therapies.
More clinical trials are required before new natural compounds and herbs can be used to treat chronic hypertension and its ramifications, such as respiratory distress syndrome and kidney failure.
Khaled A et al. · Phytotherapy research : PTR (2023)
Alkaloids, amino acids, anthocyanidins, flavonoids, glucosinolates, isoflavonoids, phenolic acids, polyphenolics, and triterpenoids are among the bioactive metabolites pocessing an impressive ACE inhibitory activity.
Many herbs including Rosmarinus officinalis, Hibiscus sabdariffa, Curcuma longa, Rauwolfia serpentina, Emblica officinalis, Cynara scolymus, Punica granatum, Mucuna pruriens, Capsicum annuum, and Moringa olifera were found having ACE inhibitory activities comparable to captopril and enalpril.
These enticing natural ACE inhibitors deserve to be a safeguard medicine against hypertension, respiratory distress syndrome, and chronic kidney diseases.
4Safety and efficacy of Mucuna pruriens in Parkinson's diseaseSystematic ReviewCited 8×2024
This manuscript summarizes the knowledge gained about MP by the authors, focusing on how to cultivate, store, and provide it to patients in the safest and most effective way in clinical trials.
Caronni S et al. · Parkinsonism & related disorders (2024)
This manuscript summarizes the knowledge gained about MP by the authors, focusing on how to cultivate, store, and provide it to patients in the safest and most effective way in clinical trials.
We aim to increase clinical trials investigating its safety and efficacy in PD, before promoting individual use of MP on a global scale, particularly in countries where availability and affordability of levodopa-based medications is still limited.
6Neuroprotection by Mucuna pruriens in neurodegenerative diseasesSystematic ReviewCited 14×2022
Zahra W et al. · Neurochemical research (2022)
It aims to summarize the medicinal importance of Mucuna pruriens in treatment of these diseases, and put forward the potential targets where Mucuna pruriens can act for therapeutic interventions.
In this review, the effect of Mucuna pruriens on ameliorating the neurodegeneration evident in PD, AD, ALS and stroke is briefly discussed.
The potential targets for neuroprotection by the plant are delineated, which can be studied further to validate the hypothesis regarding the use of Mucuna pruriens for the treatment of these diseases.
Scientific evidence supports the use of mucuna and ashwagandha as phytotherapics for improving serum T concentrations and semen parameters.
Santos HO et al. · Journal of ethnopharmacology (2019)
Scientific evidence supports the use of mucuna and ashwagandha as phytotherapics for improving serum T concentrations and semen parameters.
Despite inconclusive evidence for use of tribulus as a T booster, it may provide advantageous effects on sperm parameters in men with idiopathic infertility.
Nutraceutical strategies and some phytotherapics may also be effective to promote prostate health.
Further, collaborative efforts at isolating pro-drug candidates from medicinal plants for studies at the molecular, cellular and clinical level towards elucidating their mechanisms of action on the testes are therefore warranted in the light of the current male fertility crisis.
Abarikwu SO et al. · Andrologia (2020)
There still appear to be many more extracts of medicinal plants that have not been characterised to determine the phytochemicals unique to them that have target effects on the gonads.
9Role of herbal products in Parkinson's disease treatmentSystematic ReviewCited 38×2018
The present review may be beneficial for designing future drugs for effective treatment of PD.
Amro MS et al. · La Clinica terapeutica (2018)
In the present narrative review, the main aim is to discuss the pathogenesis of PD, define the role of different potential herbal extracts on its pathogenesis which may form the basis of treatment.
We also discuss in detail the active chemical compounds present each herb which are effective in the treatment of PD.
The present review may be beneficial for designing future drugs for effective treatment of PD.
10Systematic ReviewCited 33×2017
Ayurveda with its medicinal plants and treatment approaches, can strengthen the therapeutic armamentarium of PD to improve clinical outcomes, if these leads are systematically further investigated by well-designed longer term studies.
Pathak-Gandhi N et al. · Journal of ethnopharmacology (2017)
Ayurveda with its medicinal plants and treatment approaches, can strengthen the therapeutic armamentarium of PD to improve clinical outcomes, if these leads are systematically further investigated by well-designed longer term studies.
It is evident that redox stabilization and replenishment of mitochondrial function seem to be an important therapeutic approach against PD as both are required for optimal neuronal functioning.
Srivastav S et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2017)
It is evident that redox stabilization and replenishment of mitochondrial function seem to be an important therapeutic approach against PD as both are required for optimal neuronal functioning.
Enormous research done in this field has shown that some natural and synthetic products exhibit neuroprotective and anti-apoptotic potential by improving mitochondrial function and alleviating oxidative stress.
Further studies are recommended for obtaining more conclusive results about the efficacy and safety of the mentioned medicinal plants.
Tahvilzadeh M et al. · Andrologia (2016)
Male factors account for 20%-50% of cases of infertility.
For some of them, including Chlorophytum borivilianum, Crocus sativus, Nigella sativa, Sesamum indicum, Tribulus terrestris, Mucuna pruriens and Withania somnifera, more reliable evidence was found.
The mechanisms involved in the beneficial effects of medicinal plants in sperm abnormalities are antioxidant, anti-inflammatory, anti-oedematous and venotonic activity as well as containing precursors for sperm production and increasing blood testosterone level.
Hence, the present review has been emphasized on the nutritional potential of this underutilized, nonconventional legume and current state of its utilization as food/feed for both human beings and livestock throughout the world.
Pugalenthi M et al. · Plant foods for human nutrition (Dordrecht, Netherlands) (2005)
Recently, the velvet beans are exploited as a protein source in the diets of fish, poultry, pig, and cattle after subjected to appropriate processing methods.
Although the velvet beans contain high levels of protein and carbohydrate, their utilization is limited due to the presence of a number of antinutritional/antiphysiological compounds, phenolics, tannins, L-Dopa, lectins, protease inhibitors, etc., which may reduce the nutrient utilization.
Unfortunately, even though many researchers all over the world working on Mucuna, only scanty and conflicting information are available regarding its utilization as a food/feed and no scientific gathering to date has focused on the food/feed applications of Mucuna.
15Quality of life and motor symptoms improvementRCTCited 1×2026
To confirm long-term safety and efficacy, larger international multicenter, double-blind trials with extended follow-up (e.g. 24-36 months) and ethnically diverse cohorts are needed.Registered at PACTR201611001882367.
Cilia R et al. · Journal of Parkinson's disease (2026)
Huge benefit
← WorseNo effectBetter →
Could be chance
Adverse events were more frequent with MP (56% vs. 37.5%, p = 0.48), though the difference was not statistically significant.
Most were mild, with only 12.5% leading to discontinuation.ConclusionsMP could be a cost-effective alternative for PD individuals with limited access to commercial levodopa formulations.
Safety measures included recording any adverse event and laboratory test.ResultsMP powder improved quality of life, motor and non-motor symptoms over 12 months, demonstrating similar outcome to LD + DDCI on all endpoints.
17Drug bioavailability and motor symptomsRCTCited 4×n=11 · very small study2025
Boonmongkol T et al. · Journal of neural transmission (Vienna, Austria : 1996) (2025)
Huge benefit
← WorseNo effectBetter →
The geometric mean ratio was 155.67% (90% CI 134.59-180.04), exceeding the bioequivalence acceptance range of 80-125%.
Mild and transient adverse events, such as nausea and dizziness, were more frequently associated with MP.
MP offers superior drug exposure and extends the ON state without increasing dyskinesia, positioning it as a promising alternative to synthetic levodopa for managing motor symptoms.
18UPDRS motor score improvementsRCTn=75 · small study2024
This RCT provides important long-term comparative data for Mucuna pruriens as a levodopa source in Parkinson's disease, particularly relevant for global access to treatment.
Cilia R et al. · Parkinsonism & Related Disorders (2024)
Mucuna pruriens produced comparable UPDRS motor score improvements to conventional levodopa over 12 months
Safety profile was similar between groups, with dyskinesia rates not significantly different
Mucuna pruriens was substantially less costly, supporting its use in low-resource settings
20Clinical benefit and tolerabilityCrossoverCited 40×n=14 · very small study2018
The overall benefit provided by MP on the clinical outcome was limited by tolerability issues, as one could expect by the relatively rapid switch from LD/CD to levodopa alone in advanced PD.
Cilia R et al. · Parkinsonism & related disorders (2018)
Huge benefit
← WorseNo effectBetter →
Seven patients (50%) discontinued MP prematurely due to either gastrointestinal side-effects (n = 4) or progressive worsening of motor performance (n = 3), while nobody discontinued during the LD/CD phase.
The overall benefit provided by MP on the clinical outcome was limited by tolerability issues, as one could expect by the relatively rapid switch from LD/CD to levodopa alone in advanced PD.
Larger parallel-group studies are needed to identify appropriate MP formulation (e.g. supernatant water), titration scheme and maintenance dose to minimize side-effects in the long-term.